Remember this one - 29 March 2017, its now December 2018 and nothing happened
PERTH, AUSTRALIA – 29 March 2017: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has entered into a feasibility agreement with Pfizer Consumer Healthcare.
Under the agreed work plan, SUDA will apply its proprietary OroMist® oro-mucosal spray technology to two over-the-counter (OTC) molecules for evaluation by Pfizer.
Mr Stephen Carter, SUDA’s CEO and Managing Director, commented: “We are delighted to be working with Pfizer to assess the feasibility of two interesting drugs with our OroMist® platform, where we believe that our technology can offer a unique advantage.”
Expand
